Clinical Trials · NCT06584916

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

Name: A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Orforglipron Tirzepatide Semaglutide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Eli Lilly and Company
Enrollment: 376
Start date: Sep 2024
Locations: 29 sites, United States, Puerto Rico
Primary endpoint: Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5

View Orforglipron compound reference